Content about Renal dialysis

September 4, 2012
Impax settles with Genzyme over kidney dialysis drugs

Generic drug maker Impax Labs has settled with a subsidiary of Sanofi regarding generic versions of two drugs for dialysis patients, Impax said Tuesday.

HAYWARD, Calif. — Generic drug maker Impax Labs has settled with a subsidiary of Sanofi regarding generic versions of two drugs for dialysis patients, Impax said Tuesday.

Impax announced a settlement with Genzyme concerning generic versions of Renvela (sevelamer carbonate) 800 mg tablets and 2.4 g and 0.8 g oral suspension and Renagel (sevelamer hydrochloride) tablets in the 400 mg and 800 mg strengths.

June 28, 2012
Botanical Labs launches gluten-free protein liquid supplement

Botanical Labs on Wednesday launched its certified gluten-free Protein Complete liquid dietary supplement that is fortified with 10 g of protein per 1-oz. serving.

FERNDALE, Wash. — Botanical Labs on Wednesday launched its certified gluten-free Protein Complete liquid dietary supplement that is fortified with 10 g of protein per 1-oz. serving.

Wellesse Protein Complete and the entire Wellesse line of supplements target:

  • Consumers requiring rapid absorption and ease of dosing in liquid nutritional sources during critical recovery and ongoing malabsorption maintenance, following bariatric surgery and other medical procedures;

January 12, 2012
Active Health Foods rolls out Active X bar for dialysis patients

Active Health Foods has introduced an energy bar designed for dialysis patients.

RIVERSIDE, Calif. — Active Health Foods has introduced an energy bar designed for dialysis patients.

The Active X double chocolate chip bar is made with an exclusive, proprietary formula and joins the company's current lineup of energy bars sold under the Active X and Active X Plus brands.

February 8, 2011
Vascugel granted fast-track designation by FDA

The Food and Drug Administration has given expedited review to a drug for preventing hemodialysis failure in patients with end-stage kidney disease.

CAMBRIDGE, Mass. — The Food and Drug Administration has given expedited review to a drug for preventing hemodialysis failure in patients with end-stage kidney disease.

The FDA granted fast-track review status to the cell-based therapy Vascugel, made by Pervasis Therapeutics. The FDA grants the status to accelerate review of treatments for serious and life-threatening conditions, particularly those that address serious, unmet medical conditions.

December 1, 2010
Keryx: Zerenex reduces phosphate levels in patients on kidney dialysis

Drug maker Keryx Biopharmaceuticals got promising results from a late-stage clinical trial of a drug for treating elevated phosphate levels, also known as hyperphosphatemia, in patients on kidney dialysis, the company said Tuesday.

NEW YORK — Drug maker Keryx Biopharmaceuticals got promising results from a late-stage clinical trial of a drug for treating elevated phosphate levels, also known as hyperphosphatemia, in patients on kidney dialysis, the company said Tuesday.

In a phase-3 trial, Zerenex (ferric citrate) significantly reduced phosphate levels in patients with end-stage kidney disease on dialysis.

September 28, 2010
Keryx commences phase-3 trial for Zerenex

Keryx has begun its phase-3 clinicial trial of a drug designed to treat elevated serum...

NEW YORK Keryx has begun its phase-3 clinicial trial of a drug designed to treat elevated serum phosphorous levels in patients with end-stage renal disease on dialysis.

July 12, 2010
Watson seeks FDA approval for generic Renvela, confirms patent challenge

Generic drug maker Watson Pharmaceuticals hopes to be the first to market a version of...

MORRISTOWN, N.J. Generic drug maker Watson Pharmaceuticals hopes to be the first to market a version of a kidney disease treatment made by Genzyme, Watson said Monday.

Watson said it filed a regulatory approval application with the Food and Drug Administration for sevelamer carbonate for oral suspension. The drug is a generic version of Genzyme’s Renvela, used to control serum phosphorus in patients with chronic kidney disease who are on dialysis.

 

July 5, 2010
Impax challenges Renvela patent

Generic drug maker Impax Labs is challenging the patent on a drug used to treat...